Reference Detail

Ref Type
PMID
Authors Manish Aghi, Michael Vogelbaum, Steven Kalkanis, Daniela Bota, Bob Carter, Clark Chen, Bradley Elder, Johnathan Engh, Samuel Goldlust, George Kaptain, Santosh Kesari, Joseph Landolfi, Linda Liau, Tom Mikkelsen, David Piccioni et. al.
Title COMPLEMENTARY CLINICAL AND ANCILLARY DATA FROM 123 PATIENTS WITH RECURRENT HIGH GRADE GLIOMA FROM THREE PHASE 1 TRIALS OF TOCA 511 AND TOCA FC: UPDATE AND JUSTIFICATION FOR A PHASE 2/3 TRIAL
Journal Neuro Oncol
Vol
Issue
Date
URL http://neuro-oncology.oxfordjournals.org/content/18/suppl_6/vi18.2.abstract?sid=a0cb3fc1-c011-4ac9-814c-2056450bbaa4
Abstract Text Neuro Oncol (2016) 18 (suppl 6): vi18.

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Therapy Description
Drug Name Trade Name Synonyms Drug Classes Drug Description
Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown malignant glioma not applicable Toca 511 + Toca FC Phase I Actionable In a Phase I trial, Toca 511 and Toca FC demonstrated safety and preliminary efficacy, with median overall survival ranging from 12.1 to 13.6 months in patients with recurrent high grade glioma (Neuro Oncol (2016) 18 (suppl 6): vi18.; NCT02414165). detail...